Jannie Borst obtained a Master degree in Biology with Chemistry at Leiden University. She did the major part of her PhD work at Harvard Medical School, where she identified the CD3 complex on T lymphocytes. She obtained her PhD degree from Leiden University in 1985. In 1987, she started her independent career at the Netherlands Cancer Institute, with a Huygens fellowship from The Netherlands Organization for Scientific Research. In 1992, she became staff scientist at the NKI-AVL and from 2002 to 2019, she was the head of the Division of Immunology. From 1999-2019, she was in addition professor in Experimental Oncology at the University of Amsterdam. Since 2019, she is the head of the Department of Immunohematology and Blood transfusion at Leiden University Medical School.
Her research line concerns molecular mechanisms governing the T cell response, with focus on dendritic cell interactions, costimulatory molecules, associated signaling pathways and gene expression programs. In collaboration with dr. Hans van Eenennaam of Aduro Biotech Europe and team, she has brought the initial discovery of a costimulatory receptor to an immunotherapeutic drug that is in phase 2 testing in cancer patients. She also explores the concept of "immunogenic cell death", combining expertise in immunology with her expertise in cell death.
- 2019: Distinguished lecturer at annual research conference, LUMC, Leiden
- 2019: Elected member of the Academia Europea
- 2018: Delphine Parrott Memorial lecturer, West Scotland Immunology group, Glasgow University, UK
- 2013: Award from Nanjing Medical University, Nanjing, China
- 2012: Member of the European Molecular Biology Organization (EMBO)
- 2010: Bronze medal from Tohoku University School of Medicine, Sendai, Japan
- 2009: Van Loghem lecturer, career award from the Dutch Society for Immunology(NVVI)
- 1992: Lord Litchfield lecturer, Oxford University, UK
- 1987: Constantijn & Christiaan Huygens fellowship of the Netherlands Organization for Scientific Research (NWO)
- Borst J, Ahrends T, Bąbała N, Melief CJ, and Kastenmüller W. CD4+ T-cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18: 635-647, 2018.
- Cuadrado E, van den Biggelaar M*, de Kivit S*, Chen Y-Y, Slot M, Doubal I, Meijer A, van Lier RAW, Borst J* & Amsen DA*.Quantitative proteomics reveals a unique wiring of signaling pathways that defines human regulatory T cell identity. *equal contribution. Immunity 48: 1046-1059, 2018.
- Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, Jacobs H & Borst J. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 47: 848-861, 2017.
- Hendriks J, Gravestein LA, Tesselaar K, van Lier RAW, Schumacher TNM& Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1: 433-440, 2000.
- Borst J, van de Griend RJ, van Oostveen JW, Ang S-L, Melief CJ, Seidman JG & Bolhuis RLH. A T cell receptor γ/CD3 complex found on cloned functional lymphocytes. Nature (article) 325: 683-688, 1987.